Lanreotide , as compared with placebo , was associated with significantly prolonged progression-free survival ( median not reached vs. median of @ months , P < @ by the stratified log-rank test ; hazard ratio for progression or death , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ) .